Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026470 | 0.77 | HSD17B10 (0.39) | — | |
| SCHEMBL3833251 | 0.77 | HSD17B10 (0.39) | — | |
| SCHEMBL30001804 | 0.77 | DPP4 (0.32) | KMT2A | |
| SCHEMBL19994348 | 0.77 | DPP4 (0.32) | KMT2A | |
| SCHEMBL19994376 | 0.77 | DPP4 (0.32) | KMT2A | |
| SCHEMBL14826522 | 0.77 | TSHR (0.34) | KMT2A | |
| SCHEMBL6921106 | 0.69 | MMP2 (0.36) | — | |
| SCHEMBL2576147 | 0.69 | MMP2 (0.36) | — | |
| SCHEMBL1250785 | 0.69 | MMP2 (0.36) | — | |
| SCHEMBL12837924 | 0.69 | ACE (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | KMT2A 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.